What You Should Know
- The Deal: Merck and Mayo Clinic have signed a strategic research agreement to apply AI and multimodal data to drug discovery. This is Mayo Clinic’s first collaboration of this scale with a global biopharma company.
- The Data: Merck gains access to Mayo Clinic Platform_Orchestrate, a treasure trove of de-identified clinical data, genomic datasets, lab results, imaging, and clinical notes from the world’s top-ranked hospital system.
- The Focus: The partnership will initially target three high-need areas: Inflammatory Bowel Disease (IBD), Atopic Dermatitis, and Multiple Sclerosis. The goal is to use AI to identify better drug targets and validate models using real-world evidence.
The “Orchestrate” Advantage
For years, the holy grail of drug discovery has been “real-world evidence.” Pharmaceutical companies spend billions testing drugs in sterile, controlled clinical trials, often failing because they lack insight into how diseases actually manifest in the messy, complex real world. Merck just bought itself a map to that world.
The centerpiece of the deal is Mayo Clinic Platform_Orchestrate. Most data deals involve handing over a static dataset (a CSV file of patient records). Mayo’s platform is different; it is an “architecture” that allows Merck to run its AI models inside Mayo’s secure environment.
This grants Merck access to “multimodal” data that is notoriously hard to get:
- Clinical Notes: The unstructured doctor’s scrawl that contains the nuance of a diagnosis.
- Genomics: The DNA blueprints of patients.
- Pathology & Imaging: The visual evidence of disease progression.
By training its “virtual cell” technologies on this real-world data, Merck aims to spot drug targets that traditional methods miss.
Targeting Three Key Diseases
The partners aren’t trying to boil the ocean. They are starting with three specific therapeutic areas where advanced analytics can make an immediate impact:
- Gastroenterology: Specifically, Inflammatory Bowel Disease (IBD).
- Dermatology: Atopic Dermatitis.
- Neurology: Multiple Sclerosis.
In each of these areas, patient response to treatment is highly variable. One drug might work for Patient A and fail for Patient B. Merck is betting that Mayo’s deep longitudinal data can reveal the why behind that variance.By combining Mayo Clinic Platform’s de-identified data, clinical expertise and Platform technology with Merck’s world-class research and development capabilities, we are poised to speed innovative breakthroughs to patients and redefine drug development,” said Gianrico Farrugia, M.D., president and CEO, Mayo Clinic. “This collaboration represents a new present and future for healthcare — one where platform-based collaboration leads to more answers, more cures and better outcomes for patients worldwide.”
